Browse studies
Find your next paid study
4 recruiting studies matching your filters
Phase 1
MAGENTA: Phase I Study of Mezigdomide and Talquetamab in Relapsed and Refractory Multiple Myeloma
This is a phase 1 study to find the recommended dose and schedule of mezigdomide and talquetamab in relapsed and refractory multiple myeloma (RRMM), and to tes…
Relapsed Refractory Multiple Myeloma (RRMM)
Massachusetts General HospitalNCT07032714
Phase 2
A Phase 2 Study of Elranatamab in Combination With Isatuximab (ELISA) in Relapsed and Refractory Multiple Myeloma
This is an open-label phase 2 study of elranatamab in combination with isatuximab administered subcutaneously in patients with relapsed and refractory multiple…
Relapsed Refractory Multiple Myeloma (RRMM)Relapsed Refractory Multiple Myeloma
Massachusetts General HospitalNCT06832865
Phase 3
An Open-label, Randomized, Phase 3 Study of Linvoseltamab (REGN5458; Anti- BCMA x Anti-CD3 Bispecific Antibody) Versus the Combination of Elotuzumab, Pomalidomide, and Dexamethasone (EPd), in Patients With Relapsed/Refractory Multiple Myeloma (LINKER-MM3)
This study is researching an experimental drug called linvoseltamab, also called REGN5458. Linvoseltamab has previously been studied by itself (without other …
Relapsed Refractory Multiple Myeloma (RRMM)
Regeneron PharmaceuticalsNCT05730036
Phase 2
A Phase 2 Study of Radiotherapy-induced Immune Priming to Enhance Elranatamab (Elra) in Relapsed Refractory Multiple Myeloma (RRMM) With Extramedullary Disease (EMD) and Paramedullary Disease (PMD) "PRIME-EMD-PMD"
To learn if low doses of radiation therapy can help the drug elranatamab enhance the killing effect of the cancer cells.
Phase 2Radiotherapy-Induced Immune PrimingElranatamab+4 more
M.D. Anderson Cancer CenterNCT07382739